5-IAI

The human dosage of 5-IAI has been described as 100 to 200{{nbsp}}mg and its duration of action as 2 to 4{{nbsp}}hours. Human anecdotal reports suggest that 5-IAI is entactogenic and that it increases sociability and trust. On the other hand, it is reported that 5-IAI produces very little euphoria and is far less stimulating than MDMA and other amphetamines. Relatedly, 2-aminoindanes like 5-IAI never gained widespread popularity as recreational drugs, probably due to their relative lack of euphoria.

Similarly to MDMA, 5-IAI acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).{{cite journal | vauthors = Oeri HE | title = Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy | journal = J Psychopharmacol | volume = 35 | issue = 5 | pages = 512–536 | date = May 2021 | pmid = 32909493 | pmc = 8155739 | doi = 10.1177/0269881120920420 | url = }} Its {{Abbrlink|EC₅₀|half-maximal effective concentration}} values for induction of monoamine release have not been reported. In any case, its relative potency for monoamine release is serotonin > dopamine > norepinephrine. In addition, 5-IAI's affinity (K_i) values for the monoamine transporters are 879{{nbsp}}nM for the serotonin transporter (SERT), 311{{nbsp}}nM for the norepinephrine transporter (NET), and 992{{nbsp}}nM for the dopamine transporter (DAT), whereas its values in terms of functional inhibition have been reported to be 241{{nbsp}}nM or 2,500{{nbsp}}nM at the SERT, 612{{nbsp}}nM or 760{{nbsp}}nM at the NET, and 992{{nbsp}}nM or 2,300{{nbsp}}nM at the DAT in two different respective studies.

In addition to its interactions with the monoamine transporters, 5-IAI shows high affinity for the serotonin 5-HT_1A, 5-HT_2A, 5-HT_2B, and 5-HT_2C receptors, as well as affinity for the α_2A-, α_2B-, and α_2C-adrenergic receptors. The high affinity for the serotonin receptors is in contrast to MDAI.

5-IAI and MDAI fully substitute for MDMA in drug discrimination tests in rodents. This suggests that they produce MDMA-like subjective and entactogenic effects in rodents.

Unlike related 2-aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats (15% or less reduction of serotonergic markers), but is less neurotoxic than its corresponding amphetamine homologue para-iodoamphetamine (pIA) and the doses employed have been described as "extremely high". In any case, regular high-dose 5-IAI has been found to produce cognitive and memory deficits in rodents.

Scheduled in the "government decree on psychoactive substances banned from the consumer market".https://finlex.fi/fi/lainsaadanto/2014/1130

Sweden's public health agency suggested classifying 5-IAI as a hazardous substance, on September 25, 2019.{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/september/tretton-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/ | title=Tretton ämnen föreslås klassas som narkotika eller hälsofarlig vara | publisher=Folkhälsomyndigheten | language=sv | date=25 September 2019 | access-date=11 November 2019 | archive-date=31 October 2019 | archive-url=https://web.archive.org/web/20191031144424/https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/september/tretton-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/ | url-status=dead }}

{{Reflist}}

{{Entactogens}}

{{Monoamine releasing agents}}

{{Serotonin receptor modulators}}

{{Adrenergic receptor modulators}}

{{Monoamine neurotoxins}}

{{DEFAULTSORT:Iodo-2-aminoindane, 5-}}

Category:2-Aminoindanes

Category:Entactogens

Category:Monoaminergic neurotoxins

Category:Serotonin-norepinephrine-dopamine releasing agents